More News

Cognition Therapeutics Launches $45.2 Million Upsized IPO
Cognition Therapeutics Launches $45.2 Million Upsized IPO

Cognition Therapeutics, a company targeting age-related diseases of the retina and central nervous system (CNS), announced Oct. 8 an upsized initial public offering of nearly 3.8 million shares of ...

Skye Bioscience Announces $7 Million Registered Direct Offering
Skye Bioscience Announces $7 Million Registered Direct Offering

Skye Bioscience announced Sept. 29 that it had closed on a registered direct offering of 77.8 million shares of its common stock, equivalents, or warrants, at $0.09 per share, for gross proceeds of...

Factors Driving Retinal Pharma Pipelines are Injection Interval, Safety, and Price
Factors Driving Retinal Pharma Pipelines are Injection Interval, Safety, and Price

Longer injection intervals without gene therapy might be the theme for retinal pharmaceuticals in 2021, thanks to subsidiaries of the Roche Group filing marketing applications in the US and Europe ...

AAO Museum of the Eye Opens to Public
AAO Museum of the Eye Opens to Public

The American Academy of Ophthalmology (AAO) has opened its Truhlsen-Marmor Museum of the Eye in San Francisco, the group announced Sept. 29. The 3,500-square-foot museum is located on the ground fl...

H.I.G. Capital Acquires Aspire Pharma
H.I.G. Capital Acquires Aspire Pharma

Private equity firm H.I.G. Capital reported Sept. 24 that one of its affiliates had acquired Aspire Pharma, a UK-based provider of niche generic and branded specialty pharmaceuticals. Financial ter...

China’s Neurophth Opens Manufacturing Facility for Ophthalmic Gene Therapies
China’s Neurophth Opens Manufacturing Facility for Ophthalmic Gene Therapies

China’s Neurophth Biotechnology reported Sept. 27 that it had opened a new state-of-the-art manufacturing facility for gene therapy products at the Phase II Suzhou Biomedical Industrial Park in Suz...

Pharos Capital Acquires Vantage Outsourcing, a Provider of Cataract Logistics Support
Pharos Capital Acquires Vantage Outsourcing, a Provider of Cataract Logistics Support 

Private equity firm Pharos Capital Group announced Sept. 22 that it had acquired Vantage Outsourcing, a cataract surgical service provider based in Effingham, Illinois. Vantage, founded in 1995, pr...

Oak Bay Biosciences Plans to Crowdfund CAD $1 Million for Stargardt Candidate
Oak Bay Biosciences Plans to Crowdfund CAD $1 Million for Stargardt Candidate

Oak Bay Biosciences, of Victoria, British Columbia, is attempting to raise CAD $1 million in equity through a crowdfunding campaign on Canada’s FrontFundr platform to advance a Stargardt treatment ...

AAO Meeting Attendees Must Verify COVID-19 Vaccination Through Clear Health Pass App
AAO Meeting Attendees Must Verify COVID-19 Vaccination Through Clear Health Pass App

The American Academy of Ophthalmology (AAO) says that all in-person attendees of the AAO annual meeting in New Orleans will have to show proof of COVID-19 vaccination using the Clear Health Pass ap...

IrisVision Introduces Lightweight Inspire Headset for Low Vision
IrisVision Introduces Lightweight Inspire Headset for Low Vision

IrisVision, of Pleasanton, California, announced Sept. 21 the US launch of its streamlined low-vision headset Inspire. IrisVision’s smart software lens technology restores vision by capturing real-...

Study Shows Strong Correlation Between Test Results of Heru’s re:Vive and Humphrey Field Analyzer
Study Shows Strong Correlation Between Test Results of Heru’s re:Vive and Humphrey Field Analyzer

Miami-based Heru reported Sept. 22 that visual field test results from its wearable platform, re:Vive, were strongly correlated with results from the Zeiss’ Humphrey Field Analyzer (HFA) in a study...

RegeneRx Says Acquisition of Korean Partner Could Boost its Dry Eye Candidate
RegeneRx Says Acquisition of Korean Partner Could Boost its Dry Eye Candidate

Maryland-based RegeneRx Biopharmaceuticals announced Sept. 27 that GtreeBNT, the licensee for several RegeneRx product candidates, is being acquired by HLB Group, a Korean company that includes six...

Eyevensys Partners with Phillips-Medisize, Minnetronix Medical on Gene Therapy Delivery System
Eyevensys Partners with Phillips-Medisize, Minnetronix Medical on Gene Therapy Delivery System

Eyevensys announced Sept. 27 that it had entered into strategic engagements with medical device manufacturers Phillips-Medisize and Minnetronix Medical to develop next-generation technology for the...

First Patient in Germany is Implanted with Pixium Vision’s Prima System
First Patient in Germany is Implanted with Pixium Vision’s Prima System

France-based Pixium Vision announced on Sept. 23 the first implantation of a patient in Germany in the PRIMAvera pivotal trial of its Prima subretinal miniature photovoltaic wireless implant. The s...

Ophthalmologist Marnix Heersink, MD, Donates $95 Million to Medical School
Ophthalmologist Marnix Heersink, MD, Donates $95 Million to Medical School

The University of Alabama at Birmingham announced Sept. 28 that its medical school would be named the UAB Marnix E. Heersink School of Medicine in honor of longtime supporter and ophthalmologist Ma...

Axim Appoints Joseph Tauber, MD, as Chief Medical Officer
Axim Appoints Joseph Tauber, MD, as Chief Medical Officer

Axim Biotechnologies, of San Diego, reported Sept. 21 that it had appointed Joseph Tauber, MD, as chief medical officer and chairman of its medical advisory board. The company is developing rapid d...

US, UK Join EU in Approving First Ranibizumab Biosimilar Byooviz
US, UK Join EU in Approving First Ranibizumab Biosimilar Byooviz

The UK and US have joined the European Union in approving their first ranibizumab biosimilar, Byooviz, a Samsung Bioepis product that references Lucentis. EU approval was handed down Aug. 18. UK ap...

Diagnostic Device Makers Luneau, Optovue Announce Merger
Diagnostic Device Makers Luneau, Optovue Announce Merger

Ophthalmic diagnostic device manufacturers Luneau Technology, of France, and Optovue, of Fremont, California, have announced an agreement to merge. Terms of the deal were not disclosed. The compani...

Aerie Removes CEO After Dry Eye Candidate Misses Phase IIb Targets
Aerie Removes CEO After Dry Eye Candidate Misses Phase IIb Targets

Aerie Pharmaceuticals announced Sept. 21 that it had terminated longtime chairman and chief executive officer Vicente Anido, PhD, just days after the company reported that its dry eye candidate AR-...

Nicox Blepharitis Candidate NCX 4251 Misses Endpoints in Phase IIb Trial
Nicox Blepharitis Candidate NCX 4251 Misses Endpoints in Phase IIb Trial  

French company Nicox announced Sept. 23 that NCX 4251, its candidate for blepharitis, failed to meet its primary or secondary endpoints in the MISSISSIPPI Phase IIb trial. NCX 4251 is a novel paten...

Arctic Vision Adds Mydriatic Candidate MydCombi to Eyenovia License Deal
Arctic Vision Adds Mydriatic Candidate MydCombi to Eyenovia License Deal

China’s Arctic Vision announced Sept. 16 that it would expand its exclusive license agreement with Eyenovia to include a third asset, mydriatic candidate MydCombi, for development and commercializa...

Novartis Acquires Arctos Medical, Expanding Optogenetic Gene Therapy Pipeline
Novartis Acquires Arctos Medical, Expanding Optogenetic Gene Therapy Pipeline

Swiss company Novartis announced Sept. 21 that it had acquired Arctos Medical, developer of a potential optogenetic AAV gene therapy for inherited retinal disease. Financial details were not disclo...

Coave, Théa to Co-develop Gene Therapy Candidate for PDE6b-Associated RP
Coave, Théa to Co-develop Gene Therapy Candidate for PDE6b-Associated RP

French companies Coave Therapeutics and Théa have agreed to co-develop Coave’s gene therapy candidate CTx-PDE6b for patients with PDE6b-associated retinitis pigmentosa. Théa will make an upfront pa...

Glaukos Licenses Attillaps’ Compounds to Eradicate Demodex Mites
Glaukos Licenses Attillaps’ Compounds to Eradicate Demodex Mites

Glaukos announced Sept. 20 that it had entered into a licensing agreement with Attillaps Holdings granting Glaukos global rights to develop and commercialize Attillaps’ library of compounds that ta...

Retinal Degeneration Fund Launches Opus Genetics with $19 Million in Seed Funding
Retinal Degeneration Fund Launches Opus Genetics with $19 Million in Seed Funding

The Retinal Degeneration Fund (RD Fund), the venture arm of the Foundation Fighting Blindness, announced Sept. 22 that it had launched Opus Genetics to develop gene therapies for orphan inherited r...

2021 Euretina Congress Draws Record Turnout, Lauds Controversy as Educational
2021 Euretina Congress Draws Record Turnout, Lauds Controversy as Educational

Thomas Wolfensberger, MD, captured the spirit of the 2021 Euretina congress when he praised the meeting’s debates by paraphrasing a quote that he never learned anything from anyone who agreed with ...

Ophthalmic Company Revenue Increases 44.2 Percent in Second Quarter of 2021
Ophthalmic Company Revenue Increases 44.2 Percent in Second Quarter of 2021

Overall ophthalmic revenue in Q2-2021 totaled $11.1 billion, indicating a strong recovery from a pandemic-impacted Q2-2020. Eight public companies reported record-high earnings in Q2-2020 compared ...

Surgeons Report 65.6 Percent Increase in Q2-2021 Ophthalmic Procedure Volume
Surgeons Report 65.6 Percent Increase in Q2-2021 Ophthalmic Procedure Volume

US ophthalmologists reported that ophthalmic procedures increased 65.6 percent in Q2-2021 compared with COVID-19-impacted Q2-2020, according to Market Scope’s latest surveys. Year-over-year perform...

APAO Virtual Meeting Focuses on Changes in Delivery of Eye Care
APAO Virtual Meeting Focuses on Changes in Delivery of Eye Care

The 36th Asia-Pacific Academy of Ophthalmology (APAO) Congress convened on a virtual platform on Sept. 5 after the COVID-19 pandemic forced the cancellation of the 2020 meeting. During the course o...

Byooviz Becomes First Ranibizumab  Biosimilar Approved in the EU, UK, US
Byooviz Becomes First Ranibizumab Biosimilar Approved in the EU, UK, US

The European Union, UK, and US all have approved their first ranibizumab biosimilar, Byooviz, a Samsung Bioepis product that references Lucentis. EU approval was handed down Aug. 18. UK approval fo...

Arctic Vision Gets Green Light for China’s First Phase III Study of Presbyopia Treatment
Arctic Vision Gets Green Light for China’s First Phase III Study of Presbyopia Treatment

Arctic Vision announced Sept. 2 that Chinese regulators had given it the go-ahead to begin a Phase III study of ARVN003 (pilocarpine microdose ophthalmic solution) for the treatment of presbyopia. ...

Melt Secures Financing for Trial of Candidate for Pain and Sedation
Melt Secures Financing for Trial of Candidate for Pain and Sedation

Melt Pharmaceuticals announced Sept. 2 that it plans to begin a Phase II study of its pain and sedation drug candidate, MELT-300, after receiving a $13.5 million senior secured loan from parent Har...

Solving Ophthalmic Telehealth Issues Requires New Tech and Regulatory Clarity, Surgeon Says
Solving Ophthalmic Telehealth Issues Requires New Tech and Regulatory Clarity, Surgeon Says

Telehealth’s future in ophthalmology is teetering between potential and uncertainty, according to Grayson W. Armstrong, MD, MPH, an ophthalmologist at Massachusetts Eye and Ear in Boston and instru...

Select US FDA Approvals and Clearances in August 2021
Select US FDA Approvals and Clearances in August 2021

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in August 2021, according to the agency’s database. CenterVue gained clearance for additional featu...

Two Research Grants Are Among Latest Ophthalmic Fundraising
Two Research Grants Are Among Latest Ophthalmic Fundraising

The Gilbert Family Foundation, based in Detroit, is funding a study to investigate optic pathway tumors in patients with neurofibromatosis type 1. Entrepreneur Steve Kirsch is supporting a collabor...

AbbVie, Regenxbio to Partner on Wet AMD Gene Therapy Candidate
AbbVie, Regenxbio to Partner on Wet AMD Gene Therapy Candidate

AbbVie and Regenxbio announced Sept. 13 that they would partner to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (we...

New Diagnostic Testing of Astronauts’ Vision Uses Mobile Technology, Machine-Learning
New Diagnostic Testing of Astronauts’ Vision Uses Mobile Technology, Machine-Learning

European researchers are testing a new way to monitor astronaut eye health with diagnostic equipment that launched to the International Space Station on Aug. 29 from NASA’s Kennedy Space Center in ...

Ivantis Settles Glaukos’ Patent Suit, Faces Another from Sight Sciences
Ivantis Settles Glaukos’ Patent Suit, Faces Another from Sight Sciences

Just as Glaukos and Ivantis were reporting a settlement in the patent infringement lawsuit filed by Glaukos against Ivantis’ Hydrus Microstent glaucoma device, Sight Sciences issued its own legal c...

Glaukos Files for Supplemental Approval in US of iStent Infinite
Glaukos Files for Supplemental Approval in US of iStent Infinite

Glaukos announced Sept. 3 that it had submitted a supplemental premarket approval (PMA) application to the US FDA for the iStent Infinite trabecular micro-bypass system for glaucoma. The Infinite w...

COVID-19 Backlog to Boost Single-Use Device Market 6 Percent
COVID-19 Backlog to Boost Single-Use Device Market 6 Percent

Global increases in ophthalmic surgery—driven by a pandemic-created surgery backlog and the world’s aging population—will lead to nearly 6 percent per year revenue growth in single-use surgical dev...

Enthusiasm Wanes for Pegcetacoplan as Apellis Releases Phase III Results
Enthusiasm Wanes for Pegcetacoplan as Apellis Releases Phase III Results

The enthusiasm for pegcetacoplan, a potential treatment for geographic atrophy (GA) from Apellis Pharmaceuticals, seems to be waning in the wake of the release of topline data from the Phase III st...

Novartis FocalView Device Aims to Move  Visual Acuity Testing to Patients’ Homes
Novartis FocalView Device Aims to Move Visual Acuity Testing to Patients’ Homes

The COVID-19 pandemic accelerated the search for remote monitoring applications to reduce clinic visits while simultaneously allowing doctors to monitor the health of their patients. One applicatio...

Market Scope Tracking Status of 2021 Ophthalmic Meetings
Market Scope Tracking Status of 2021 Ophthalmic Meetings

Market Scope is tracking the status of 2021 ophthalmic meetings as the world tries to recover from COVID-19. Here is the latest information: Organization Status Date Location More Information Glauc...

Market Scope’s Peter Downs  to Speak at OIS Retina@ASRS
Market Scope’s Peter Downs to Speak at OIS Retina@ASRS

Join Market Scope's Peter Downs as he delivers a special presentation on the key findings of the new "2021 Retinal Pharmaceuticals Market Report" at the Ophthalmology Innovation Source’...

Euretina Panelists Discuss Visudyne Shortage Outside US
Euretina Panelists Discuss Visudyne Shortage Outside US

The opening panel of the 2021 Euretina Congress discussed how to handle central serous retinopathy patients during the ongoing shortage of Visudyne outside the US (OUS). The Dutch Ophthalmic Societ...

Weekly Corporate Poll, September 2021
Weekly Corporate Poll, September 2021

Emerging Companies Pursuing Ophthalmic Indications, September 2021
Emerging Companies Pursuing Ophthalmic Indications, September 2021

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease. Company Location About AxeroVision Carlsbad, California The company reported Aug. 31 that it...

September 2021 Ophthalmic News Briefs
September 2021 Ophthalmic News Briefs

Boston-based TearClear reported Sept. 8 that it had filed an investigational new drug (IND) application with the US FDA to begin a registrational study of its lead glaucoma candidate, TC-002, a lat...

AbbVie, Regenxbio to Partner on Wet AMD Gene Therapy Candidate in Potential Billion-Dollar Deal
AbbVie, Regenxbio to Partner on Wet AMD Gene Therapy Candidate in Potential Billion-Dollar Deal

AbbVie and Regenxbio announced Sept. 13 that they would partner to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (we...

Ivantis Settles Glaukos’ Patent Infringement Suit over Hydrus, Faces Another from Sight Sciences
Ivantis Settles Glaukos’ Patent Infringement Suit over Hydrus, Faces Another from Sight Sciences

Just as Glaukos and Ivantis were reporting a settlement in the patent infringement lawsuit filed by Glaukos against Ivantis’ Hydrus Microstent glaucoma device, Sight Sciences issued its own legal c...

Want to Read Locked Articles?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more